Cell Cultures

Developing ACC cell lines that grow robustly and retain key biomarkers over time in culture has been challenging but there have been recent successes. Researchers should be careful to understand the provenance of any purported ACC cell line and validate known biomarkers and characteristics prior to conducting experiments.

Culture flask
Misidentified cell lines: The scientific literature remains full of purported ACC cell lines (ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2) that were found to be cross-contaminated with other cancer cell lines or non-human mammalian species (Phuchareon et al., PLoS One, 2009). Furthermore, another purported ACC cell line (SACC-83) has not been verified to harbor molecular alterations typical of ACC and does not replicate ACC morphology when injected into mice. Researchers should not view these models as valid ACC cell lines.

Immortalized cell lines with lost MYB fusions: Three ACC tumors were immortalized with HPV E6/E7 oncoproteins (UTSW-ACC52 and UTSW-ACC112; Queimado et al., Int J Cancer, 1999) or hTERT (MDA-ACC-01; Li et al., Oral Oncol, 2014). Although they retain selected characteristics of ACC, these cell lines lost the t(6;9) translocations and MYB fusions found in the primary tumors from which they were derived. Researchers should be cognizant of the limitations of these models.

Naturally-immortalized cell lines with MYB expression: Given past issues with misidentifications and lost MYB alterations, researchers should focus on ACC cell lines that harbor either (1) a characteristic MYB rearrangement, or (2) an STR profile matching a patient diagnosed with ACC by an expert pathologist and an expression pattern shared by the tumor the cell line was derived from. Fortunately, much progress has been made over the past few years as witnessed by the following examples of published ACC cell lines fitting these criteria:

Dr. Jacques Nor’s laboratory at the University of Michigan developed the UM-HACC-2A cell line from an ACC found in the minor salivary gland at the base of tongue. At early and late passage numbers, UM-HACC-2A shows an STR profile that matches the patient’s DNA, harbors the classic t(6;9) chromosomal rearrangement involving the MYB and NFIB genes, and expresses high levels of MYB protein. UM-HACC-2A has also been characterized by whole exome sequencing and RNA sequencing. Further information and culture conditions can be found in the original publication. For access to the cell line or genomic datasets, academic researchers may contact Dr. Jacques Nor ([email protected]) or Dr. Kristy Warner ([email protected]). Cells will only be shipped from the University of Michigan to outside academic laboratories under an MTA and within the United States at this time.  Cells can also be purchased from Applied Biological Materials (abm).

Dr. Frederic Kaye’s laboratory at the University of Florida developed the UFH2 cell line from a tumor biopsy taken from a patient with locally recurrent and metastatic parotid gland ACC. The UFH2 cell line shares DNA alterations (ATRX and MLL/KTM2A) originally identified in the patient’s tumor, overexpresses MYB protein up until passage 9 (subsequently losing overexpression by passage 34), and forms tumors in mice with solid histology similar to that of the primary tumor. Despite losing MYB overexpression over time, late passage UFH2 cells show a similar gene expression signature (as assessed by RNA sequencing) to other ACC tumors.

In parallel, the UFBT cell line was developed from a breast tumor that formed in Dr. Kaye’s MYB-NFIB/MMTV/Ink4a+/-/Arf+/- transgenic mouse model. UFBT cells were confirmed to harbor the MYB-NFIB transgene and show high levels of MYB protein by western blot analysis.

Both early passage UFH2 and UFBT cells are sensitive to genomic or chemical inhibition of MYB. Further information and culture conditions can be found in the original publication. For access to the cell line and genomic datasets, please contact Dr. Frederic Kaye ([email protected]).

Primary/short-term ACC cultures: Cells derived from ACC tumor tissue (biopsy, surgical specimen or PDX) that grow for a limited period of time in culture have been described in the following publications: Panaccione et al., Clin Cancer Res, 2016, Chen et al., Sci Reports, 2017, Nor et al., Clin Cancer Res, 2017, and Andersson et al., J Natl Cancer Inst, 2017. Researchers may reach out to the individual researchers for more information on these reagents. However, their widespread dissemination and use in high-throughput screening methods are likely to be limited in comparison with cell lines.

ACCRF is supporting several attempts to develop new ACC cell lines and three-dimensional organoid cultures. We will publicize these reagents as they become available.